Compare STRL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRL | IBRX |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | United States |
| Employees | 1740 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.4B |
| IPO Year | 1996 | 2015 |
| Metric | STRL | IBRX |
|---|---|---|
| Price | $431.75 | $8.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $443.33 | $12.57 |
| AVG Volume (30 Days) | 470.6K | ★ 31.2M |
| Earning Date | 05-04-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.42 | ★ 38.71 |
| EPS | ★ 9.38 | N/A |
| Revenue | ★ $957,958,000.00 | $113,288,000.00 |
| Revenue This Year | $20.76 | $88.57 |
| Revenue Next Year | $11.64 | $146.98 |
| P/E Ratio | $44.95 | ★ N/A |
| Revenue Growth | 38.81 | ★ 668.31 |
| 52 Week Low | $96.34 | $1.83 |
| 52 Week High | $477.03 | $12.43 |
| Indicator | STRL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 55.55 |
| Support Level | $385.44 | $2.27 |
| Resistance Level | $473.51 | $12.43 |
| Average True Range (ATR) | 21.02 | 0.70 |
| MACD | -1.06 | -0.20 |
| Stochastic Oscillator | 84.51 | 30.00 |
Sterling Infrastructure Inc is a construction company that specializes in heavy civil infrastructure construction and infrastructure rehabilitation as well as residential construction projects. The company operates in three reportable segments namely, Transportation Solutions, E-Infrastructure Solutions, and Building Solution. Transportation Solutions include highways, roads, bridges, airfields, ports, light rail, and others. Building Solution projects include concrete foundations for single-family homes. E-Infrastructure Solutions include the services which are provided to large, blue-chip companies in the e-commerce, data center, distribution center, and warehousing, energy, mixed-use, and multi-family sectors. The majority of the revenue is generated from E-Infrastructure Solutions.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.